Back to Search Start Over

Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.

Authors :
Yun JH
Chang E
Bae S
Jung J
Kim MJ
Chong YP
Kim S-H
Choi S-H
Lee S-O
Kim YS
Source :
Microbiology spectrum [Microbiol Spectr] 2024 Aug 06; Vol. 12 (8), pp. e0033324. Date of Electronic Publication: 2024 Jun 25.
Publication Year :
2024

Abstract

The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older ( P < 0.001) and more frequently had solid cancer ( P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent ( P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index ( P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores ( P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) ≤ 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia.IMPORTANCEIn this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.<br />Competing Interests: The authors declare no conflict of interest.

Details

Language :
English
ISSN :
2165-0497
Volume :
12
Issue :
8
Database :
MEDLINE
Journal :
Microbiology spectrum
Publication Type :
Academic Journal
Accession number :
38916352
Full Text :
https://doi.org/10.1128/spectrum.00333-24